rHEALTH

Space-validated diagnostics at your fingertips

startengine

rHEALTH is developing a portable diagnostic platform designed to deliver lab-quality blood diagnostics from a single drop. The system combines multiplexed assays, miniaturized flow cytometry, and AI-driven interpretation, delivered via a handheld device and an accompanying app. The technology originated for space applications and is being adapted for consumer and point-of-care use. The products are in advanced stages of development and will require FDA approval prior to market.

One of the initial tests is the complete blood count. The platform enables rapid testing across biomarkers, small molecules, and nucleic acids, supporting decentralized diagnostics in settings such as pharmacies, urgent care centers, and homes. The technology was validated by NASA on the International Space Station, and the company positions the system alongside its vitals monitoring device and health AI.

rHEALTH has participated in on-orbit demonstrations and has received recognition, including finalist status in the Qualcomm Tricorder XPRIZE and a Nokia Sensing XCHALLENGE winner. The company holds 17 issued patents and has secured over $20 million in non-dilutive funding from NASA, NIH, and pharmaceutical partners, with about $3 million raised in equity capital. The team is led by Harvard/MIT-trained physician Eugene Chan and includes collaborations with NASA and NIH, with regulatory expertise in ISO 13485.

Market context indicates a large global diagnostics and monitoring opportunity, with a total addressable market reported at $323 billion (2023) and projected to exceed $400 billion by 2030; the serviceable addressable market is about $224 billion, with a serviceable obtainable segment focused on hematology and patient monitoring devices at roughly $16.2 billion.

Eugene Y Chan, MD

CEO, Principal Accounting Officer and Director

Jamie Cheng

Assay QC Manager

Marcus Atkin

Industrial Designer

Dexter Eames

Hardware Engineer

Samuel Bearg

Software Engineer

The update describes the traditional blood-testing workflow, including scheduling an appointment, possible fasting, phlebotomy, shipment to a centralized processing lab, and receiving results days later through a doctor. It states that rHEALTH uses a drop of blood from a fingertip and delivers results in 15 to 20 minutes, and notes that its products require FDA clearance before market use and may never be obtained.

The Problem With the Current Blood Testing System

The update explains that rHEALTH products are in advanced stages of development and will require FDA approval before being available on the market. It describes a commercialization path starting in the United States and notes that the technology is intended to deliver blood-test results from a single drop in about 15–20 minutes with minimal power and no trained technician.

rHEALTH portable blood-testing technology: commercialization and FDA approval need

The update explains rHEALTH’s revenue model: one-time device sales (rHEALTH Awesome system), ongoing consumable cartridge purchases for monthly or daily testing, and a software subscription for AI-based health interpretation and insights. It also notes that rHEALTH products are in advanced development and will require FDA approval before going to market.

rHEALTH three-revenue-stream model (device sales, consumables, software subscription)

The update describes rHEALTH’s AI health interpretation platform that explains blood test results using established clinical reference standards in a home setting, similar to how physicians interpret results in clinical settings. It also reiterates that rHEALTH products are in advanced development and require FDA approval before being available on the market.

The AI Interpretation Layer for rHEALTH Home Blood Test Results

The update explains that rHEALTH uses a small fingertip blood sample instead of a standard venous blood draw, claiming it requires about 1,500 times less blood. It also reiterates that rHEALTH products are in advanced development and require FDA approval before they can be marketed.

What 1,500x Less Blood Actually Means

The update states NASA selected rHEALTH and funded its development over multiple years based on engineering requirements including low mass, low volume, limited power consumption, and high reliability. It also says rHEALTH is in advanced development and will require FDA approval before products can be marketed.

Why NASA Chose rHEALTH

The update explains the need for fast, accurate coagulation monitoring due to the narrow therapeutic range of blood thinners (too little risks clots; too much risks dangerous bleeding). It states that current special coagulation lab tests take a few hours versus needing results in minutes, and presents coagulation monitoring as rHEALTH’s first commercial target, with Dr. Chan describing it as potentially large enough to build a significant business before other tests on the roadmap; it also reiterates that rHEALTH products require FDA approval prior to market availability.

rHEALTH: Coagulation monitoring as first commercial target (FDA approval required)

The rHEALTH offering has been extended to August 28, 2026. StartEngine notes that because the offering changed, the SEC may require certain investments to be reconfirmed; affected investors will be contacted by email with instructions.

rHEALTH offering extended to August 28, 2026; reconfirmation may be required

rHEALTH uses a core device that stays in place while different test cartridges determine the analysis (e.g., coagulation cartridge vs. complete blood count cartridge), avoiding the need for separate machines. The company says this architecture supports expanding from two initial tests to a pipeline of more than 100 tests and notes products will require FDA approval before market availability.

How rHEALTH’s cartridge test system works

rHEALTH says founder Dr. Eugene Chan invested $2 million of his own capital before opening the campaign to outside investors. The update also states rHEALTH products are in advanced development and will require FDA approval prior to being available on the market.

Founder invested $2M personally in rHEALTH before opening the campaign

The update describes a March 19, 2022 Antares NG-17 rocket launch from Wallops Island, Virginia carrying the rHEALTH blood diagnostic system. It says ESA astronaut Samantha Christoforetti ran tests on the International Space Station using a single-drop sample, and that the findings were published in Nature Communications.

The Rocket Launch Story

Dr. Eugene Chan will explain the rHEALTH technology and how it is designed to improve patient outcomes, and discuss the investment opportunity as the company advances toward FDA registration. The webinar is on June 4 at 5 PM PT / 8 PM ET.

rHEALTH Webinar: Product reveal, patient impact, and progress toward FDA registration

StartEngine reports updates to rHEALTH’s Form C financials and that the campaign is extending to June 29, 2026. Because the SEC requires reconfirmation after changes to live offerings, investors whose subscriptions require reconfirmation will be contacted by email with instructions.

Notice of material change to rHEALTH offering; campaign extended to June 29, 2026

rHEALTH says it is adapting core technology from rHEALTH ONE used on the International Space Station (tested in 2022 by astronaut Samantha Cristoforetti) into an on-Earth consumer device, rHEALTH Awesome. The company describes the device as smaller and easier to handle, providing results in about 15–20 minutes from a small drop of blood, and states its products are in advanced development and will require FDA approval before market availability.

From space to earth: rHEALTH ONE adapted into consumer version rHEALTH Awesome

rHEALTH says it has passed $160,000 in its campaign and is working toward the $250,000 mark. The company says the funds support clinical validation studies, quality system development, and preparation for FDA registration targeted within the next year.

rHEALTH passes $160,000 in its campaign; targeting $250,000

rHEALTH says it has been featured in Nature Communications and PLOS ONE, and that the publications describe rHEALTH devices performing tests using only a drop of blood. The update also states the peer-reviewed work supports transparency and that rHEALTH products require FDA approval before being available on the market.

rHEALTH Featured in Peer-Reviewed Journals (Nature Communications, PLOS ONE)

rHEALTH says NASA selected it for testing aboard the International Space Station, and the company reports it met required benchmarks and successfully operated in space. The update also states its core technology won the $2.25 million Nokia Sensing XCHALLENGE and was a finalist in the $10 million Qualcomm Tricorder XPRIZE, while noting products require FDA approval before market availability.

rHEALTH reports NASA space testing selection and wins in Nokia Sensing XCHALLENGE/Qualcomm Tricorder XPRIZE

rHEALTH reports securing an additional $3 million from the National Institutes of Health to support development of new tests, bringing total raised to $23 million. The company says more than $20 million of total funding has come from non-dilutive sources such as NIH, NASA, and pharma partners, and that its products require FDA approval before market availability.

rHEALTH secures additional $3M NIH commitment; total raised reaches $23M

The update describes nurses, physicians, and other healthcare professionals as part of rHEALTH’s investor base supporting its Reg CF offering. It reiterates that rHEALTH products are in advanced stages of development and will require FDA approval before being available on the market.

Healthcare workers described as part of rHEALTH’s investor base

Dr. Eugene Chan founded rHEALTH after treating a patient who was nearly impossible to draw blood from, highlighting challenges in accessing reliable diagnostics. He developed a device that uses very small blood amounts to run lab-quality tests without sending samples off-site and personally invested $2 million; rHEALTH products are in advanced development and will require FDA approval before marketing.

Founder Story: Dr. Eugene Chan and rHEALTH’s small-sample diagnostics

rHEALTH says its technology can deliver results in about 15–20 minutes from a very small finger-stick blood sample, with testing covering cell counts, immune assays, biomarkers, and small molecules. The company also states astronauts operated the system aboard the International Space Station, and that rHEALTH products require FDA approval before being available on the market.

rHEALTH testing results in ~15–20 minutes using a small finger-stick sample

rHEALTH says it is working with Mayo Clinic to support clinical validation of rHEALTH Awesome, providing access to patient populations, testing infrastructure, and medical researchers. The update adds that rHEALTH products are in advanced development and will require FDA approval before reaching the market.

rHEALTH Collaboration With Mayo Clinic for Clinical Validation of rHEALTH Awesome

rHEALTH uses a cartridge-based architecture that is designed to expand the test menu over time without changing the hardware. The company says it is starting with coagulation monitoring and complete blood counts, and that its products will require FDA approval before becoming available on the market.

Building the rHEALTH Test Menu (Cartridge-Based System)

rHEALTH is positioned for chronic-condition blood testing by using a cartridge-based device that supports multiple test types, delivers results in about 15 to 20 minutes, and uses very small blood volumes. The company says its products are in advanced development and will require FDA approval before they are available on the market.

Built for the Chronic Condition Market

StartEngine reports that the rHEALTH campaign has been extended to April 30, 2026. The notice says that because the offering changed, the SEC requires certain investments to be reconfirmed, and affected investors will be contacted by email with instructions.